- Home
- FCNCP vs MIRM Comparison
FCNCP vs MIRM Comparison
Compare FCNCP & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCNCP | MIRM |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 7.2B |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FCNCP | MIRM |
|---|---|---|
| Price | $19.40 | $96.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $119.85 |
| AVG Volume (30 Days) | 11.5K | ★ 423.1K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 97.95 | N/A |
| Revenue | ★ $9,541,000,000.00 | $19,138,000.00 |
| Revenue This Year | N/A | $26.22 |
| Revenue Next Year | N/A | $22.04 |
| P/E Ratio | $0.20 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.30 | $63.23 |
| 52 Week High | $22.60 | $130.00 |
Technical Indicators
Market Signals| Indicator | FCNCP | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 28.01 | 43.98 |
| Support Level | N/A | $97.49 |
| Resistance Level | $20.64 | $105.20 |
| Average True Range (ATR) | 0.28 | 3.53 |
| MACD | -0.06 | 0.46 |
| Stochastic Oscillator | 0.00 | 39.68 |
Price Performance
Historical ComparisonAbout FCNCP First Citizens BancShares Inc.
First Citizens is a US regional bank with total assets of around $237 billion as of June 30, 2026. Headquartered in Raleigh, North Carolina, First Citizens' largest markets are North Carolina, South Carolina, and California. The bank has a track record of acquiring troubled banks from the FDIC, such as Silicon Valley Bridge Bank in 2023, which doubled its asset base. First Citizens offers products and services across retail, commercial, wealth management, and railcar leasing. First Citizens derived over 95% of its earnings from banking and less than 5% from railcar leasing in 2025.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.